UBS Group: Raises Moderna Price Target from $50 to $150

Odaily Planet Daily News: UBS Group stated that it has raised Moderna (MRNA.O) price target from $50 to $150. Previously reported, the personalized mRNA cancer vaccine developed by Moderna in collaboration with Merck achieved significant success in a Phase 3 clinical trial targeting high-risk melanoma, marking the world's first mRNA cancer therapy to prove effective in a large-scale Phase 3 trial. Following the announcement, Moderna's stock surged nearly 177% in a single day.